AstraZeneca buys into Harvard’s stem cell tech for diabetes R&D – FierceBiotech
BioPharma-Reporter.com |
AstraZeneca buys into Harvard’s stem cell tech for diabetes R&D
FierceBiotech Harvard professor Doug Melton is having quite a week. His work on potential cell therapies for diabetes just fueled the launch of a well-funded biotech startup, and now he’s signed up with AstraZeneca ($AZN) to help the drugmaker spotlight new … AstraZeneca to Collaborate with the Harvard Stem Cell Institute in DiabetesPharmacy Times (registration) AstraZeneca and Harvard Team Up on Stem Cell Therapies for DiabetesGenetic Engineering & Biotechnology News AstraZeneca Inks Collaboration With Harvard Stem Cell InstituteLondon South East BioPharma-Reporter.com all 11 news articles » |
The Globe and Mail |
Gairdners honour researcher who went from outsider to stem–cell pioneer
The Globe and Mail In the U.K., she had been studying developmental biology at a world-leading lab just as the field was making giant leaps forward, spurred by the discovery of stem cells – cells that can be coaxed to produce a variety of other cell types – and the … Ebola pioneer, stem cell researcher honoured with Canada Gairdner AwardsCBC.ca SickKids research chief wins $100000 Gairdner awardToronto Star |
The Globe and Mail |
Gairdners honour researcher who went from outsider to stem–cell pioneer
The Globe and Mail In the U.K., she had been studying developmental biology at a world-leading lab just as the field was making giant leaps forward, spurred by the discovery of stem cells – cells that can be coaxed to produce a variety of other cell types – and the … Ebola pioneer, stem cell researcher honoured with Canada Gairdner AwardsCBC.ca SickKids research chief wins $100000 Gairdner awardToronto Star |
Channel News Asia |
BioLineRX stem cell leukemia drug meets goals in early trial
Reuters Current stem cell treatments require four or five days of injections of material from a donor to get into the bloodstream, but BioLineRX said its treatment, currently called BL-8040, needed just one. “The results support BL-8040 as a one-day, single … BioLineRx Reports Successful Top-Line Safety and Efficacy Results for Novel …Business Wire (press release) |
Channel News Asia |
BioLineRX stem cell leukaemia drug meets goals in early trial
Reuters Current stem cell treatments require four or five days of injections of material from a donor to get into the bloodstream, but BioLineRX said its treatment, currently called BL-8040, needed just one. “The results support BL-8040 as a one-day, single … BioLineRx Reports Successful Top-Line Safety and Efficacy Results for Novel …Business Wire (press release) Leukemia Drug Shows Promise in Early TrialNewsmax |
Channel News Asia |
BioLineRX stem cell leukaemia drug meets goals in early trial
Reuters Current stem cell treatments require four or five days of injections of material from a donor to get into the bloodstream, but BioLineRX said its treatment, currently called BL-8040, needed just one. “The results support BL-8040 as a one-day, single … BioLineRx Reports Successful Top-Line Safety and Efficacy Results for Novel …Business Wire (press release) Leukemia Drug Shows Promise in Early TrialNewsmax |